We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Observational study shows long-term safety and efficacy of ponatinib in chronic myeloid leukemia, indicating its role for intolerant patients.
No takes yet. Share an insight, caveat, or question.
Breccia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: